Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ginkgo Bioworks Holdings Inc. Class A

An announcement from Doric Nimrod Air Three ( ($GB:DNA3) ) is now available. Doric Nimrod Air Three Limited has announced the posting of its Notice...

Doric Nimrod Air Three Announces Annual General Meeting

DeNA Co ( ($DNACF) ) has released its Q2 earnings. Here is a breakdown of the information DeNA Co presented to its investors. DeNA Co., Ltd. is a J...

DeNA Co. Reports Strong Financial Growth

BMO Capital analyst Etienne Ricard maintained a Hold rating on Canadian Tire today and set a price target of C$180.00. Ricard covers the Financial ...

BMO Capital Remains a Hold on Canadian Tire (CDNAF)

DeNA Co ( ($JP:2432) ) just unveiled an announcement. DeNA Co., Ltd. has announced a new policy initiative aimed at enhancing management practices ...

DeNA Co. Announces New Management Policy for Sustainable Growth

DeNA Co ( ($JP:2432) ) has shared an announcement. DeNA Co., Ltd. has announced the establishment of the Delight Ventures Builder III Investment Li...

DeNA Co., Ltd. Strengthens AI Focus with New Investment Partnership

DeNA Co ( ($JP:2432) ) has shared an announcement. DeNA Co., Ltd. reported a significant increase in its financial performance for the six months e...

DeNA Co. Reports Robust Financial Growth in First Half of 2025

In a report released yesterday, from Bank of America Securities maintained a Sell rating on Ginkgo Bioworks Holdings. The company’s shares closed y...

Bank of America Securities Remains a Sell on Ginkgo Bioworks Holdings (DNA)

In a report released yesterday, Tamy Chen from BMO Capital maintained a Hold rating on Canadian Tire, with a price target of C$180.00. The company’...

Canadian Tire (CDNTF) Receives a Hold from BMO Capital

Ginkgo Bioworks Holdings, Inc. ( ($DNA) ) has released its Q3 earnings. Here is a breakdown of the information Ginkgo Bioworks Holdings, Inc. prese...

Ginkgo Bioworks Reports Q3 2025 Financial Results

CareDx ( ($CDNA) ) has shared an announcement. On November 4, 2025, CareDx announced its third-quarter financial results, highlighting a 21% year-o...

CareDx Reports Strong Q3 Financial Results

Doric Nimrod Air Three ( ($GB:DNA3) ) has shared an update. Doric Nimrod Air Three Limited has announced the successful sale of its Airbus A380-861...

Doric Nimrod Air Three Completes Airbus A380 Sale to Emirates

Medicenna Therapeutics (($TSE:MDNA)) announced an update on their ongoing clinical study. Medicenna Therapeutics is conducting a Phase 1/2 clinical...

Medicenna’s MDNA11 Study: A Potential Game-Changer in Cancer Treatment?

The latest announcement is out from CareDx ( ($CDNA) ). On October 22, 2025, CareDx, Inc. appointed Suresh Gunasekaran as a Class II director. Mr. ...

CareDx Appoints Suresh Gunasekaran as New Director

Medicenna Therapeutics Corp ( ($TSE:MDNA) ) has provided an announcement. Medicenna Therapeutics Corp announced that updated clinical data from the...

Current Quarter	$-1.8	Next Quarter	$NA
Current Year	$-5.94	Next Year	$-4.33
QoQ Growth	NaN%	YoY Growth	+27.1%
3Y EPS CAGR	+42.0%	Target Price	$10.67
Consensus	Buy	Upside	+30.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DNA	$8.17	+4.48%	1.05M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DNA	$8.17	+4.5%	1.05M
3
4
5
6

DNA

DNA

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Ginkgo Bioworks Holdings Inc. Class A Data in Excel

Get Ginkgo Bioworks Holdings Inc. Class A Data in Excel